The IOCB Prague was incorporated in 1953 as a part of the Czech Academy of Sciences. Already in early seventies first drugs developed by IOCB Prague scientists entered market. These drugs were commercialized through collaboration with local pharmaceutical company SPOFA and later with company Ferring. Great success of the research of prof. Antonín Holý brought antiviral drugs which were commercialized in collaboration with KU Leuven and US company Gilead Sciences. These drugs represent one of the main pillars in the treatment of HIV and HBV patients. Over last decade we have signed several license agreements with pharmaceutical companies and currently there are more than 10 projects in a preclinical development running at the IOCB Prague.
Published Date: 2020-09-16;